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3D-domain swappingProtein aggregation via 3D domain swapping is a complex mechanism which can lead to the acqui-
sition of new biological, benign or also malignant functions, such as amyloid deposits. In this con-
text, RNase A represents a fascinating model system, since by dislocating different polypeptide chain
regions, it forms many diverse oligomers. No other protein displays such a large number of different
quaternary structures. Here we report a comparative structural analysis between natural and arti-
ﬁcial RNase A dimers and bovine seminal ribonuclease, a natively dimeric RNase with antitumor
activity, with the aim to design RNase A derivatives with improved pharmacological potential.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bovine pancreatic ribonuclease (RNase A, EC 3.1.2.27.5) has
been the object of many innovative studies in different ﬁelds,
including protein chemistry, enzymology, evolutionary and struc-
tural biology [1]. RNase A represents an extraordinary model sys-
tem for many biophysical studies, and it is one of the most
represented proteins in PDB. It also inspired the hypothesis of pro-
tein oligomerization through the mutual exchange of identical
structural elements [2], however it took almost thirty years before
the ﬁrst X-ray structures showing this interchange were solved
[3,4] and even longer before the ﬁrst RNase A dimeric N-terminal
swapped structure (ND) was determined [5]. Later on, with the dis-
covery of the C-terminal swapped dimer (CD), RNase A became the
ﬁrst protein known to be able to oligomerize by swapping different
segments of its structure [6,7]. This ﬁnding gave a new impulse to
the ﬁeld of 3D domain swapping (3D-DS) because, based on the
structure of CD, the hypothesis of a relationship between 3D-DS
and amyloidogenic protein aggregation was put forward [6,8]. To
date, more than 300 swapped structures have been deposited inthe PDB and in a dedicated database [9], but RNase A is unique
in the diversity and number of its quaternary structures, in native
or recombinant forms, all of which preserve the catalytic activity.
Beside cleaving RNA, some ribonucleases (RNases) belonging to
different sources are endowed with other biological activities of
potential pharmacological interest [10], such as tumour treatment,
angiogenesis, immunosuppression and antimicrobial actions.
However to date, these studies have been essentially limited to
the preclinical stage, except for onconase, a frog RNase which
reached phase IIIb in clinical trials for treating certain cancers [11].
To be effective as antitumor drugs, RNases must be efﬁciently
delivered to the speciﬁc cells; for RNases this depends on the dis-
tribution of charges on the protein surface [12,13]. Strategies to
overcome this drawback which limits the potency of RNases have
been very recently reviewed [14]. Furthermore, in mammalian
cells, most monomeric, pancreatic-like RNases are captured by
RNase inhibitor (RI), a very abundant, horse-shoe shaped protein
[15], which makes an extremely tight complex (Kd <1015 M) with
RNase A and most other mammalian RNases [16,17].
Protein engineering of the RNase contact sites to inhibit the
binding with RI [18–20], chemical modiﬁcations [21] or the
conversion of the protein into a swapped, covalent dimer [22,23]
produced RNase A derivatives with higher antitumor activity. How-
ever, none of them is as cytotoxic as bovine seminal ribonuclease
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shares about 80% of sequence identity with RNase A and very close
structural and dynamical features in solution [25]. BS-RNase is
characterized by two intersubunit disulﬁde bonds and the co-exis-
tence of two isomers: a swapped (MxM) and an unswapped one
(M = M), whose relative populations are about 2:1 at equilibrium
[26]. Structural and functional studies on BS-RNase [27,28] and hu-
man pancreatic ribonuclease derivatives [29] have indicated that
BS-RNase’s cytotoxic activity is mainly due to the optimal quater-
nary assembly of the non-covalent swapped form of the enzyme
(see below). In contrast, RNase A dimers are endowedwith a limited
cytotoxic activity [30] and they are bound by RI [31]. Furthermore,
no RNase A dimeric variant displaying a relative subunit orientation
that enables the evasion of RI binding [16] under the reducing cyto-
sol conditions [32,33], has been yet produced.
Here we compare the main structural features of known bovine
RNase dimers with those of other dimeric antitumor proteins
belonging to the RNase A family, with the aim of providing insight
for engineering improved variants for potential pharmacological
applications [32,34].
2. RNase A artiﬁcial aggregates
RNase A (Fig. 1A) is almost unique in its remarkable capacity to
self-associate through 3D-DS [4,35], thus, without covalent modi-










Fig. 1. Structures of RNase A, swapped isomer of BS-RNase, and of the principal RNase
N-swapped domains (left, blue segment), from the ones, which have more C-swapped do
C-termini, respectively, are coloured distinctly from the green core of the protein to hig
BS-RNase covalent native dimer (PDB entry 1BSR); (D) RNase A CD (PDB entry 1F0V); (E
N- and C-termini with the blue and red subunits located on its left and right, respec
close-ended thanks to co-existing double domain swappings. (F) 3D-DS cyclic C-trimer, o
to form. (G) 3D-DS cyclic trimer model: the same exclusive C-swapping event could perm
model, l-NCNTT. (I) ‘‘Quasi-linear’’ N+C+N-swapped modeled tetramer, ql-NCNTT. (L) B
open interfaces located inside the dotted black circles. (M) Linear C+N+C-swapped tet
N = NC–C–CTT. (O) ‘‘Flower-cup-like’’ C-swapped-only-tetramer, CTT. (P) Tandem, fusion-BS-RNase [38] and cyanovirin N [39] were discovered to be able
to form different aggregated conformers via 3D-DS.
In 1962, the group lead by the Nobel prize winners Stein and
Moore envisaged the exchange (that is, 3D-DS) of S-peptides moi-
eties (i.e., the N-termini) between two RNase A monomers to ex-
plain the presence of dimers and larger aggregates after
lyophilization of the enzyme from 40% to 50% acetic acid aqueous
solutions [2]. All RNase A domain-swapped dimers and multimers
characterized to date are meta-stable, soluble and biologically ac-
tive, as are several oligomers formed by more than 40 3D-DS
self-associating proteins [40].
Interestingly, upon oligomerization RNase A partly maintains
its enzymatic activity against single strand RNA (ss-RNA) and,
moreover, it acquires a depolymerase action on double strand
RNA (ds-RNA) [41]. By swapping both the N- and C-termini, which
are located outside the disulﬁde-bond core and contain the catalyt-
ically important histidines 12 and 119, respectively, RNase A
reconstitutes an active site [2,5,6,42,43] with a composite func-
tional unit (F.U.) [35], in which one histidine belongs to one sub-
unit whilst Lys41 and the second histidine are provided by the
partner subunit. This active site represents part of the dimer’s
‘‘Closed interface’’, i.e., the interface present in both monomer
and 3D-DS oligomers [43], whereas in contrast the ‘‘Open inter-
face’’ is formed only upon swapping [43].
RNase A dimers and oligomers have been extensively studied in










A dimers and 3D-DS oligomers. The dashed line divides the tetramers with more
mains shown on the right (red line segment). (A) RNase A: the blue and red N- and
hlight their role in 3D-DS. (B) RNase A ND, (PDB entry 1A2W). (C) 3D-DS isomer of
) N+C-doubly-DS trimeric RNase A model: the central green subunit swaps both its
tively; this model represents the ﬁrst seed of a ‘‘runaway 3D-DS’’, which can be
r CT (PDB entry 1JS0): the C-termini-only swapping allows a propeller-like structure
it a ‘‘ﬂower-cup-like’’ C-trimer to be formed. (H) Linear N+C+N-swapped tetrameric
ent N+C+N-swapped tetrameric model, b-NCNTT [68], displaying two additional
rameric model, CNCTT. (N) C-swapped-cyclic + Nswapped-linear tetrameric model,
peptide linked, unswapped RNase A dimer (PDB entry 3MWQ).
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tial seed of a poly-N or poly-Q expansion [6]. Anyhow, neither wild
type RNase A (as described below), nor its glycosylated form,
RNase B [61], nor RNase S [62] have been shown to form amyloid
or amyloid-like ﬁbrils, but RNase B does form 3D-DS dimers and
possibly oligomers [61] while RNase S forms a relatively unstable
CD [62].
2.1. RNase A 3D-DS dimers
The RNase A N-terminus (residues 1–15), coloured in blue in
Fig. 1A, consists of an a-helix formed by residues 3–13 connected
with the protein body by a ﬂexible loop (residues 16–22). This loop
can be cleaved by subtilisin to form RNase S [63], which prompted
Moore and co-workers to hypothesize the N-terminus swapping
event [2,42]. The 3D structure of such a dimer (Fig. 1B), called ND
[37], was solved in 1998 by Eisenberg and colleagues (PDB entry,
1A2W) [5]. Each N-terminal helix swaps onto the core domain (res-
idues 23–124) of the complementary monomer to form a dimer.
The ﬂexible loop adopts two different conformations in the sub-
units, one more extended, the other forming a novel helical tract
[5]. This asymmetry, whose existence in solution is supported by
data obtained with subtilisin [44], was proposed to stabilize the di-
mer by providing six H-bonds at the ‘‘Open interface’’, i.e., the
interface present only in the swapped oligomer(s) [43]. These H-
bonds link the anti-parallel b-strands (residues 97–103) from each
complementary subunit. Consequently, three b-strands of each
subunit combine to form an extended six-stranded sheet
(Fig. 1B), yielding a quaternary structure that is remarkably differ-
ent from that of BS-RNase [3,64] (Fig. 1C; PDB entry, 1BSR). In the
seminal protein, the Open interface (24–33 residues) [3] is formed
by two a-helices and is constrained and stabilized by two ‘‘anti-
parallel’’ disulﬁde bridges forming between Cys31 and Cys32 of
one BS-RNase subunit with Cys32 and Cys31, respectively, of the
partner. These two cysteines are unique to BS-RNase.
The second RNase A dimer, called CD [37], has a different qua-
ternary structure compared to those of ND and of BS-RNase. At
the RNase A C-terminal region, two b-strands form a b-hairpin
(residues 105–124), that is richer in hydrophobic residues than
the N-terminus. The C-terminal b-strand (residues 116–124, red
in Fig. 1A) can be detached from the protein core to accommodate
into a complementary subunit and form the CD [37], whose struc-
ture (Fig. 1D) was solved in 2001 [6] (PDB entry, 1F0V). While its
hinge loop (residues 112–115) is shorter than the one of ND (resi-
dues 16–22), its overall shape is more extended and less compact
than that of ND [6], and Molecular Dynamics (MD) simulations
indicate that CD is more ﬂexible than ND [45,46]. Their different
dimensions explain why the two isoforms can be partially sepa-
rated utilizing size exclusion chromatography [47]. In addition,
the more elongated CD exposes more positive charges than ND, so
that the two conformers can be completely separated through cat-
ion-exchange chromatography [48,65].
RNase A monomer naturally forms traces of ND [36,66]. Re-
cently, RNase A has been shown to fold partly as a dimer, most
likely as CD, in the ER of live cells [50] and both dimers can also
be produced by incubating highly concentrated monomer solu-
tions without lyophilization [36]. Furthermore, several years ago
RNase A aggregates were also detected upon interaction of the en-
zyme with substrate [67].
As reported before, structural studies on RNase A oligomers,
especially on CD, have provided insights into the formation of amy-
loid-like conformations [6]. Nevertheless, RNase A, has proven to
be not amyloidogenic under several experimental conditions
[68,69], as for example reducing conditions affecting its disulﬁdes
[56]. The incapability of RNase A to undergo ﬁbrillization is partic-
ularly intriguing if we consider that its N-terminal hinge loopharbours a ﬁbre-forming sequence, 15-SSTSAASS-22 [60]. The only
pancreatic-type RNase which recently showed to form ‘amyloid-
like’ ﬁbrils is the eosinophil cationic protein (ECP) [70].
Contrarily, when an appropriate amyloidogenic sequence, such
as poly-Q, is inserted into the C-terminal hinge loop of RNase A, or
a poly-G increases the length of the N-terminal hinge loop, the pro-
tein forms native-like amyloid ﬁbril, even under relatively mild
conditions [68,71]. Thus, proteins like RNase A have been consid-
ered to ‘‘self chaperone’’ themselves; that is, the native protein
structure holds amyloidogenic segments in safe conformations
that inhibit their amyloid formation [68,69].
Anyway, the ability of RNase A to swap both N- and C-termini
allows the enzyme to dramatically increase its ‘Swapping Capacity’
(SC = N2 + N, with N = number of swappable domains) [72] and
consequently to form several oligomeric conformers and traces of
high-order multimers [57], as will be described in detail in the next
section.
2.2. RNase A 3D-DS multimers
Besides dimers, RNase A also forms several 3D-DS multimers,
ranging from trimers to hexamers [48,57] and up to decatetra-
mers [73] that have been totally or partly characterized
[7,35,48,53,57,58]. For each oligomer size, two or more conform-
ers exist, indicating the high structural versatility of the enzyme,
even though its overall tertiary structure remains unaffected by
the 3D-DS phenomenon [74]. While the crystal structure of one
cyclic C-swapped-only trimer (C-trimer, or CT) was solved [7]
(PDB entry 1JS0, Fig. 1F), models were proposed for a second cyc-
lic C-trimer [7] (Fig. 1G), six tetramers (Fig. 1H–O) [35,53,55,58],
and for several pentamers, hexamers, and so on [57,58]. In an-
other modelled trimer, NC-trimer, or NCT (Fig. 1E), both N- and
C-swapping co-exist in the same molecule. A ‘‘quasi-linear’’ asym-
metric molecule forms, with a central doubly N+C-swapped F.U.
(i.e., displaying the green ‘‘core’’ in Fig. 1E) that displays a cata-
lytic triad with the residues derived from all the three subunits.
Experimental data [7,53] conﬁrm the reliability of this model
and suggest the possibility to expand the linear or quasi-linear,
or bent alternating N/C swapping to form tetramers (three NCN-
swapped, Fig. 1H–L; one CNC-swapped, Fig. 1M), pentamers and
so on, to grow as runaway-swapped multimers [35,58]. Further-
more, the capability to form linear and/or cyclic structures with
two different swapping domains of the same molecule, the asym-
metry of ND [5,45,53], and the ﬂexibility of the CD hinge loop [46],
encouraged the efforts to model and analyze numerous different
multimeric 3D-DS RNase A linear + cyclic quaternary structures
[35,55,57,58]. As an example, two different NCN-tetramers, appar-
ently almost identical except one is linear and the second is ‘‘qua-
si-linear’’ or partially bent, (Fig. 1H and I) were modelled [58].
These two structures are diastereomers, due to different confor-
mations, ranging from compact to extended, of the four N-term
hinge-loops [58]. The bending can increase thanks to the ﬂexibil-
ity of the C-swapping Open interface [46] to form a new NCN-con-
former with an additional interface indicated by dashed black
lines in Fig. 1L [58].
The fact that all RNase A multimers are enzymatically and bio-
logically active [30,48] further encouraged these investigations. In
particular, several experimental studies produced and character-
ized artiﬁcial wt or mutated RNase dimers and/or multimers that
display high stability [22,23,32], efﬁcient cell–membrane interac-
tion [13,23,29,75], increased evasion of RI [23,33], and conse-
quently, an elevated cytotoxic activity [76]. An interesting
example of these RNases, which will be discussed in detail below,
is the artiﬁcial unswapped tandem-dimeric RNase A [77] (Fig. 1P,
PDB entry 3MWQ), whose stability and capacity to evade, at least
partially, RI, endow it with cytotoxicity [78].
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RNase A has a high conformational stability, and it is stabilized
by four disulﬁde bonds. To form oligomers, the native monomers
must ﬁrst be denatured by heat or chemical denaturants, like ace-
tic acid, and then conditions must become less severe so that
refolding occurs and oligomers can form. The N- and C-termini
lay outside these disulﬁde bond cross-links so they can undergo
3D-DS. Nevertheless, they are ﬁrmly held by non-covalent interac-
tions to the protein core, so vigorous denaturation conditions are
needed to detach them and enable their swapping.
As reported above, the earliest method to form RNase A oligo-
mers was discovered by Crestﬁeld, Stein and Moore over 50 years
ago. They incubated the protein in 40–50% acetic acid at room tem-
perature for an hour and then lyophilized it. After redissolving the
protein in a benign buffer such as phosphate, RNase A dimers were
detected. Based on elegant chemical modiﬁcation and biochemical
experiments [1,42], this team proposed that acetic acid treatment
lead to local structural perturbations that permit the dimer to form
by swapping of N-termini between the subunits. However, incuba-
tion in 40–50% acetic acid is now known to unfold RNase A; only a
minor fraction of the native a-helical structure is maintained and
the b-sheet structure and tertiary contacts break down [79]. Pro-
lines 93 and 114, which adopt the cis conformation in native RNase
A, adopt a trans conformation upon unfolding in 40% acetic acid
[79]. Following lyophilization and re-dissolving in a benign buffer,
the presence of trans proline conformers and high protein concen-
trations favors the formation of oligomers [79]. In fact, Pro114 is
trans in CD [6,80], and mutational studies have provided some
additional evidence for the key role of proline isomerization in
RNase A oligomer formation [80], while elegant investigations
have shown that the trans Pro isomer plays a role in the relative
populations of the dimers [81]. In this context, CD is 3.5–4 times
more abundant than ND [48], while the concentration of the re-dis-
solved lyophilized protein powder and macromolecular crowding
affects the oligomerization yield [82].
A second approach to form RNase A oligomers consists of heat-
ing concentrated solutions of RNase A monomers in alcohol/water
mixtures which permit, upon cooling, oligomer formation [36]. CD
spectroscopy shows that RNase A is denatured in water/alcohol
mixtures at the temperatures that promote oligomerization [79].
The relative yields of ND and CD depend on the heating conditions
and on the identity of the alcohol or co-solvent and its concentra-
tion [36]. In particular, the CD’s yield prevails over ND’s under vig-
orous unfolding conditions, while under rather mild conditions the
relative proportions of the dimers invert [36]. This is evidence that
the N-terminal swap domain, which is rich in charged and hydro-
philic residues, is easier to detach than the hydrophobic C-terminal
swap domain, as also suggested UV spectroscopy performed at
increasing temperature [36]. These ﬁndings have been corrobo-
rated and elaborated also by mutational studies [51].
2.4. Conformation–activity relationships of RNase A 3D-DS oligomers
As noted above, RNase A forms a very large number of oligomers
[48,55,57,58] with a great variety both in the number of subunits as
well as in their arrangement (see Fig. 1). This diversity suggests the
existence of small energy differences among the various oligomers
during their formation. Nevertheless, after their formation, there
are strikingdifferences in the conformational stabilities of the RNase
A oligomers, as judged by their distinct dissociation rates [73]. In
general, larger oligomers dissociate faster than smaller ones
[53,73], but it is still debated if C-swapped dimers or oligomers dis-
sociatemore slowly than the corresponding N-swapped conformers
[51] or vice versa [59,83]. In fact, the stabilization of the oligomeric
isoforms depends on several parameters, such as temperature, pH,phosphate concentration, protein concentration, and the mutation
of key residues [23,51,53,59,73,82,83], although this feature needs
to be further investigated [59]. The various RNase A oligomers show
remarkably different enzymatic [48] and biological [30] activities.
Oligomers are less active towards ss-RNA, but are more active on
ds-RNA than the native monomer [41,48]; they are also more cyto-
toxic and better at reducing the size of human tumors [30]. Oligo-
mers that are larger or have more C-swapped interfaces are
usually more active on ds-RNA [48,57], more cytotoxic and reduce
tumor size more effectively [30]. This has been attributed to the
higher positive charge density on the larger oligomers and those
containing a prevalence of C-swapped subunits [41,48].3. Conformation–activity relationship of BS-RNase, a template
for RNase A 3D-DS dimers
An approach to obtain RNase A derivatives with increased cyto-
toxicity for tumor cells is based on the conversion of the protein
into a stable homodimeric enzyme, through the introduction of
two disulﬁde bridges between the two subunits [22], and utilizing
BS-RNase (Fig. 1C) as template. Engineering the sequences of RNase
A and BS-RNase is also an effective way to identify the structural
determinants which confer the special biological functions of the
bovine seminal enzyme [23]. The current model for BS-RNase cyto-
toxicity is that in the reducing environment of cytosol, the unswap-
ped form (M = M) dissociates into monomers [84], which are
strongly inhibited by RI binding (Fig. 2A), whereas the swapped iso-
mer (MxM) remains as a non-covalent dimer (NCD), which evades
RI (Fig. 2B). Analysis of the NCD-BS-RNase X-ray structure [28]
has suggested that Pro19 and Leu28 play important roles in this
process. Pro19 limits the ﬂexibility of the hinge peptide and forces
it to adopt a compact structure which, in turn, favours a compact
(‘‘closed’’) quaternary assembly of the protein. Leu28 provides
hydrophobic contacts at the intersubunit interface which further
stabilizes this ‘‘closed’’ structure. This suggestion was conﬁrmed
by the determination of the crystal structures of various isomers
of the BS-RNasemutant in which both these residues were replaced
by the corresponding ones of RNase A [33]. Indeed, the crystallo-
graphic studies performed on the different forms of the Pro19Ala/
Leu28Gln (PALQ) mutant revealed that the structures of its MxM
and M =M dimers are very similar to those of the corresponding
forms of the wild type protein. In contrast, the quaternary structure
of the NCD of PALQ (NCD-PALQ) [33] is very different from those of
MxM and NCD-BS-RNase [28]. This difference has been proposed to
dramatically affect the ability of these oligomers to interact with RI
based on modeling studies showing that RI will trap NCD-PALQ
effectively (Fig. 2C). This ﬁnding is in good agreement with the
functional data, since PALQ’s cytotoxicity is much lower than BS-
RNase’s [28,33]. PM8, a dimeric human pancreatic RNase variant
which has a Pro at position 19 but lacks Leu28, possesses a com-
pletely different quaternary structure [85]. The cytotoxicity of this
HP-RNase variant is strongly inhibited by RI binding (Fig. 2D).
3.1. Designed covalent dimeric RNase A derivatives and their
cytotoxicity
On the basis of BS-RNase structure–function relationship data,
several potentially cytotoxic dimers of RNase A have been produced
and characterized by introducing in the sequence of the pancreatic
enzyme, Leu28, Cys31, Cys32 (LCCmutant) and Pro19 (PLCCmutant),
i.e., the corresponding residues of BS-RNase [22,76]. These substitu-
tions lead to the formation of swapped and unswapped covalent di-
mers of the pancreatic enzyme in a 1:2 (LCC) and 2:1 (PLCC) ratio
which present a limited cytotoxic activity, independently of their
swapping propensity. The structural analysis of non-covalent
Fig. 2. Ribbon diagrams of some RI–RNase(s) complexes. (A) Experimentally-determined structure of the RI–RNase A complex (1DFJ). In the other panels the modelled
structure of other RI–RNase complexes are shown: in particular, between RI and (B) NCD-BSRNase, (C) NCD-PALQ, (D) PM8, (E) HHP2-RNase, (F) NCD-PLCC.
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[32], revealed that the dimers adopt an opened quaternary structure
that does not prevent the binding of RI, thus offering a possible expla-
nation for their low cytotoxic activity (Fig. 2F).
Moreover, the introduction of the BS-RNase’s hinge sequence
together with Cys31 and Cys32, but not Leu28, did not produce
RNase A variants with increased cytotoxic power [23,32]. Interest-
ingly, the comparison between the structures of these mutants and
those of NCD-BS-RNase and of RNase A ND [32] suggests that the
presence of a glycine at the beginning of the hinge loop (Gly16),
in addition to Pro19 and Leu28, can play a crucial role in altering
the conformation of ND and in driving the formation of the NCD-
BS-RNase’s compact quaternary structure [28].
These data were indirectly corroborated by [23] RNase A mu-
tants in which the full N-terminal hinge sequence was replaced
with that of BS-RNase, and the Ser80Arg substitution, all of which
contribute to the protein swapping capacity [59,86]. All the mu-
tants have a very low cytotoxic activity, independently of their
swapping propensity, which in some cases was as high as that of
native BS-RNase [23].
In addition, the BS-RNase and RNase A variants with Arg80 dis-
play a slightly increased percentage of swapped form compared to
the corresponding Ser80 variants [23,59,86], and also the dissocia-
tion rate of the corresponding NCD forms is decreased [23,59,87].
Overall, the data conﬁrm that, at least for RNase A, 3D-DS is an
essential requisite for cytotoxicity, because it stabilizes the dimeric
structure even in the reducing environment of the cytosol. Other
characteristics are also essential to obtain dimeric antitumor ribo-
nucleases, including a quaternary structure able to evade RI and a
high positive charge density on the N-terminal face [13,75] (Fig. 3).
Finally, RNase A dimeric variants that add the substitutions As-
p38Gly and Glu111Gly to the PLCC ones [76], thus removing two
negative charged residues on the protein surface, possess an in-
creased antitumor action, comparable to that of BS-RNase. Any-
way, no structural data are yet available for this variant.
3.2. Other covalent dimeric variants of RNase A
In addition to the introduction of disulﬁde bridges, other cova-
lent modiﬁcations of RNase A have been performed in the lastdecades to obtain stable dimeric or oligomeric derivatives. This
goal has been reached through the use of diimidoesters [88,89],
or through a zero length vacuum-heat induced side-chain amide
linkage [90]. However, the modiﬁcations introduced towards basic
residues (Lys) often limited either the catalytic [89] or the cyto-
toxic activity [91] of the products, except if artiﬁcially cationized
[91,92].
An interesting and novel dimeric RNase A variant has been ob-
tained by joining two protein molecules by a peptide linker [77]
(Fig. 1P). This RNase A tandem enzyme (RATE) is as cytotoxic as
BS-RNase and more cytotoxic than the swapped dimers of RNase
A [77]. Modelling studies on the RI–RATE interactions, based on
the crystal structure of SGRSGRSG-RATE, [78] revealed that the
engineered enzyme binds the RI with a 1:1 stoichiometry. In this
case, as suggested by the authors, the improved endocytosis efﬁ-
ciency imparted by tandemization is the ‘‘decisive factor’’ that en-
dows the enzyme with antitumor activity despite the interaction
with RI.
3.3. Designed covalent dimeric human pancreatic RNase derivatives
and their cytotoxicity
An alternative approach to obtain a potential RNase-based
chemotherapeutic agent that is more efﬁciently tolerated by the
human immune system is based on the idea of transferring
BS-RNase’s antitumor structural determinants to human RNase 1
(HP-RNase). Like RNase A, HP-RNase is a monomeric enzyme
which is very susceptible to RI inactivation. HP-RNase has been
transformed into a dimer, designated HHP-RNase, that shows
selectively cytotoxic on malignant cell lines [93]. This was
achieved by replacing Gln28, Arg31, Arg32, and Asn34 with the
corresponding residues (Leu28, Cys31, Cys32, and Lys34) from
BS-RNase. A second generation dimeric mutant of HP-RNase, desig-
nated HHP2-RNase, obtained by introducing an additional muta-
tion (Glu111Gly), was even more powerful as a cytotoxic agent
than BS-RNase, and is selective for malignant cells [94]. This pro-
tein has the obvious advantage over BS-RNase of being slightly or
non-immunogenic for humans. Like BS-RNase, HHP2-RNase folds
in unswapped and swapped forms, but in the case of the human
enzyme the swapped form is considerably less abundant. On the
Fig. 3. Schematic representation of the biological steps required for the antitumor activity of RNases. (A) Binding to the tumour cell membrane and internalization into the
cytosol. (B) Interaction with RI. (C) Upon evasion of RI cytotoxic, RNases can degrade cellular RNA and induce apoptosis.
3606 G. Gotte et al. / FEBS Letters 587 (2013) 3601–3608basis of the data obtained with BS-RNase [28,33], the high antitu-
mor action exhibited by HHP2-RNase is surprising, especially be-
cause the complex between RI and the wild-type monomeric HP-
RNase was found to be extremely stable (Kd = 2.9  1016 M and
t1/2 = 81 days). It has to be emphasized that HHP2-RNase’s inter-
subunit disulﬁde bridges are unusually stable. The crystal structure
of the unswapped form of HHP2-RNase, solved in 2009 [29], re-
vealed a quaternary structure very similar to that of BS-RNase di-
mers. However, the hinge loop, which is highly disordered in the
unswapped form of BS-RNase [95], adopts a well-deﬁned confor-
mation in both subunits of HHP2-RNase [29]. This result suggests
that this region may act as an anchor to stabilize either the
swapped or unswapped dimeric structures under reducing condi-
tions, thus making HHP2-RNase more similar to MxM and allowing
it to survive as dimer in the cytosolic compartment [29]. This ‘‘an-
chor’’ helps to maintain an appropriate quaternary shape either to
evade the interaction with RI (Fig. 2E) or to favour the formation of
the interchain disulﬁdes due to proximity of Cys31 and Cys32 of
the two subunits. This could account for HHP2-RNase’s cytotoxic-
ity. A model of this dimer, whose overall shape closely resembles
that of NCD-BS-RNase has been also obtained [29]. These data sug-
gest that in the case of HP-RNase, dimericity is more important
than swapping for cytotoxicity, in contrast to what observed for
BSRNase.
4. Concluding remarks and future perspectives
In the course of the last two decades, a huge effort has been
undertaken to develop cytotoxic variants of RNase A with im-
proved antitumor properties, but until now no RNase A variants
as powerful as BS-RNase have been produced. Studies over the last
20 years have shown that the cytotoxicity of mammalian RNases,
except ECP and EDN, relies on their ability to degrade RNA [96–
98], but it is also critically dependent on the host cell internaliza-
tion efﬁciency as well as on the ability to evade the binding of ribo-
nuclease inhibitor [96–99]. Like BS-RNase, RNase A oligomeric
aggregates stabilized through 3D-DS display improved activities
with respect to the monomeric prototype, because they are inter-
nalized with higher efﬁciency [37]. However, due to their fast dis-
sociation (low half-life in solution) and quaternary structurescompatible with RI binding, they have shown limited antitumor
activity so far. With respect to BS-RNase, RNase A has a lower pI
and less positive charge on the face interacting with membranes
[23]. Therefore, the appropriate design of variants that internalize
more efﬁciently seems a promising way to improve their pharma-
cological potential. Some monomeric RNases, like onconase
which lack the contact sites, can evade RI [99,100], and the ability
to escape RI binding can also be acquired through oligomerization.
As in the case of BS-RNase, cross-linking of protein subunits via
disulﬁde bridges can produce stable dimers which have also the
correct shape to evade RI binding. However, RNases must retain
the optimal dimeric structure even under reducing conditions to
attain a signiﬁcant antitumor activity [33]. Structural studies per-
formed on the so-called NCD forms of these variants can be very
helpful to identify which regions to modify in order to induce,
and stabilize, the right quaternary assembly.
The results obtained on the structure–function relationship and
summarized in this review clearly indicate that the potential bio-
logical activity of swapped and un-swapped RNase A oligomers, to-
gether with their structure and stability, deserves further
investigation. Along this line, protein engineering studies on pan-
creatic-like RNases should be continued to better understand the
molecular bases of the antitumor properties of these proteins
and to develop strategies to improve the shape and stability of
the dimers, even under reducing conditions. Interestingly, recent
studies indicated that the substitution of Gly16 and Arg80 could
contribute to enhance the cytotoxicity for tumour cells [23,29].
In conclusion, although aggregation studies on RNase A have
been in progress for more than 50 years [2], we are convinced that
there is plenty of room for new variants with improved activities to
be designed and developed.References
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